HIPEC Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis
Summary
The prognosis of patients with peritoneal metastasis from gastric cancer is extremely poor. Although chemotherapy combined with immunotherapy has achieved promising efficacy in the first-line treatment of advanced gastric cancer, patients with peritoneal metastasis benefit less from this regimen. Hyperthermic intraperitoneal chemotherapy (HIPEC) represents a novel treatment option, which maintains the high concentration of drugs in the abdominal cavity, and improve the anti-tumor efficacy of chemotherapy drugs through the thermo-thermal effect. The purpose of this study is to investigate the efficacy and safety of HIPEC and systemic chemotherapy combined with sintilimab in the first-line treatment of advanced gastric cancer and gastroesophageal junction adenocarcinoma with peritoneal metastasis.
Timeline
- Start
- 2024-02-20
- Primary completion
- 2027-05-30
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | 100 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | Other |
| Subject | S-1 | Small molecule | 40 mg | — |
| Subject | S-1 | Small molecule | 50 mg | — |
| Subject | S-1 | Small molecule | 60 mg | — |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | — |